Fe-N-C Nanozyme with Both Accelerated and Inhibited Biocatalytic Activities Capable of Accessing Drug-Drug Interaction

24 February 2020, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


Emerged as a cost-effective and robust enzyme mimic, nanozymes have drawn increasing attention with broad applications ranging from cancer therapy to biosensing. Developing nanozymes with both accelerated and inhibited biocatalytic properties in a biological context is highly envisioned for perusing more advanced functions of natural enzymes, such as in drug-drug interaction, but remains challenging. By re-visiting the well-known Fe-N-C electrocatalyst that has a heme-like Fe-Nx coordination active center, herein, we report that the Fe-N-C with a minimum graphitization had an even superior cytochrome P450 (CYP)-like biocatalytic activity. Moreover, the drug metabolization by the Fe-N-C upon co-existence of other foods and drugs demonstrated a trend of inhibition similar to CYP, indicating its great potential as a replacement for drug dosing guide and outcome prediction. Beyond boosting the enzyme-like activity, this work would open a new vista of nanozymes with inhibited behavior for keeping up more demanding applications, enabled by further mimicking the molecular structure of enzymes.


Drug-drug interaction

Supplementary materials



Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.